Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CRCL
MCID: CRT084
MIFTS: 26

Creatinine Clearance Quantitative Trait Locus (CRCL)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards integrated aliases for Creatinine Clearance Quantitative Trait Locus:

Name: Creatinine Clearance Quantitative Trait Locus 57
Creatinine Clearance Qtl 57 13
Crcl 57

External Ids:

OMIM 57 607135
Sources

Summaries for Creatinine Clearance Quantitative Trait Locus

About this section
MalaCards based summary : Creatinine Clearance Quantitative Trait Locus, also known as creatinine clearance qtl, is related to glioblastoma multiforme and glioblastoma. An important gene associated with Creatinine Clearance Quantitative Trait Locus is CRCL (Creatinine Clearance QTL). The drugs Valganciclovir and Colchicine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone.

More information from OMIM: 607135
Sources

Related Diseases for Creatinine Clearance Quantitative Trait Locus

About this section

Diseases related to Creatinine Clearance Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 10.3
2 glioblastoma 10.3
3 rapidly involuting congenital hemangioma 10.3
4 ovarian cancer 10.1
5 ataxia and polyneuropathy, adult-onset 10.1
6 chagas disease 10.1
7 mouth disease 10.1
8 pathologic nystagmus 10.1

Graphical network of the top 20 diseases related to Creatinine Clearance Quantitative Trait Locus:



Diseases related to Creatinine Clearance Quantitative Trait Locus
Sources

Symptoms & Phenotypes for Creatinine Clearance Quantitative Trait Locus

About this section

Clinical features from OMIM:

607135
Sources

Drugs & Therapeutics for Creatinine Clearance Quantitative Trait Locus

About this section

Drugs for Creatinine Clearance Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 302)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Colchicine Approved Phase 4 64-86-8 6167 2833
3
Fondaparinux Approved, Investigational Phase 4 104993-28-4
4
Dalteparin Approved Phase 4 9005-49-6
5
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
6
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Edoxaban Approved Phase 4 480449-70-5
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Fosfomycin Approved Phase 4 23155-02-4 446987
13
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
14
Pemetrexed Approved, Investigational Phase 4 150399-23-8, 137281-23-3 60843 446556
15
Phylloquinone Approved, Investigational Phase 4 84-80-0
16
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
17
Morphine Approved, Investigational Phase 4 57-27-2 5288826
18
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
19
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
20
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
21
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
22
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
23
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
24
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
25
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
26
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
27
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
28
Vancomycin Approved Phase 4 1404-90-6 441141 14969
29
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
30
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
31
Dabigatran Investigational Phase 4 211914-51-1
32 Menaquinone Investigational Phase 4 1182-68-9
33 Heparin, Low-Molecular-Weight Phase 4
34 PENTA Phase 4
35 Ganciclovir triphosphate Phase 4
36 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
37 Interferon-alpha Phase 4
38 interferons Phase 4
39 Hematinics Phase 4
40 Ferric Oxide, Saccharated Phase 4
41 Calamus Phase 4
42 Fibrinolytic Agents Phase 4
43 Platelet Aggregation Inhibitors Phase 4
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
45 Micronutrients Phase 4
46 Trace Elements Phase 4
47 Vitamins Phase 4
48 Antifibrinolytic Agents Phase 4
49 naphthoquinone Phase 4
50 Vitamin K Phase 4

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease Completed NCT01084278 Phase 4 Colchicine
2 Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study Completed NCT00555438 Phase 4 fondaparinux 1.5 mg/day
3 A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy Completed NCT01896297 Phase 4 Pradaxa, dabigatran etexilate
4 Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
5 A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County Completed NCT01781806 Phase 4 emtricitabine 200mg/tenofovir 300mg
6 Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairment, or End-Stage Renal Disease Undergoing Hemodialysis Completed NCT02864199 Phase 4 Peginterferon alfa-2a;Ribavirin
7 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter Completed NCT01976507 Phase 4 dabigatran etexilate mesylate
8 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study Completed NCT02503982 Phase 4 prophylactic Valganciclovir
9 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study) Completed NCT01417949 Phase 4
10 Hospitalization and Mortality in Iron Deficient, Anemic Patients With Chronic Kidney (CKD) and Heart Failure Receiving Intravenous Iron Therapy: A Five Year Follow-up From a Pilot Study Completed NCT02392910 Phase 4 Iron Sucrose;Placebo
11 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial) Recruiting NCT03061006 Phase 4 Dabigatran Etexilate;Warfarin
12 A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease Recruiting NCT03718559 Phase 4 Edoxaban;Single Antiplatelet Agents
13 Multi-center, Randomized, Open-label Trial to Evaluate the Efficacy of Oral Fosfomycin Versus Oral Levofloxacin Strategies in Complicated Urinary Tract Infections (FOCUS) Recruiting NCT03697993 Phase 4 Fosfomycin tromethamine;Levofloxacin
14 Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR) Recruiting NCT03607149 Phase 4 Pemetrexed
15 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Recruiting NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
16 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Recruiting NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
17 Evaluation of Intravenous Glucocorticoid Therapy in Total Knee Arthroplasty Recruiting NCT02219581 Phase 4 Dexamethasone 10 mg;Dexamethasone 20 mg;Standard multimodal pain management regimen;Placebo
18 Pilot Randomised Controlled Trial of Penicillin Versus Flucloxacillin for Definitive Treatment of Invasive Penicillin Susceptible Staphylococcus Aureus Not yet recruiting NCT03632642 Phase 4 Benzylpenicillin;Flucloxacillin
19 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
20 Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients Terminated NCT01786161 Phase 4 Vancomycin continuous infusion;Vancomycin intermittent dosing interval
21 Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens Terminated NCT01133600 Phase 4 Cubicin;Vancomycin
22 Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Efficacy of Alogliptin as Monotherapy or Add on Therapy in Indian Patients With Type 2 Diabetes Mellitus Withdrawn NCT03042325 Phase 4 Alogliptin
23 To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors Withdrawn NCT03676361 Phase 4 Desmopressin
24 International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
25 Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation Completed NCT00494871 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Warfarin;Rivaroxaban placebo;Warfarin placebo
26 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
27 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
28 An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed NCT01839357 Phase 3 Rivaroxaban (Xarelto, BAY59-7939)
29 A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion Completed NCT01674647 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Vitamin K antagonist (VKA)
30 A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection Recruiting NCT03830333 Phase 3 Ceftolozane/Tazobactam;Metronidazole;Meropenem;Placebo
31 Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy Recruiting NCT03869931 Phase 3 Fenofibrate
32 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET Recruiting NCT02618577 Phase 3 Edoxaban;ASA
33 Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus Recruiting NCT03232398 Phase 3 Apixaban Oral Tablet [Eliquis];Warfarin
34 A Randomized, Open Label, Active Control, 2 Parallel Groups, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Balanced Salt Solution Versus 0.9% Saline in Patients With High Risk of Contrast Induced Nephropathy. Recruiting NCT02799368 Phase 3 CJ Plasma Solution A Injection;CJ 0.9% Normal Saline Injection
35 Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin Enrolling by invitation NCT03299296 Phase 3 Rivaroxaban 10 Milligrams;Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
36 COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma Terminated NCT02739594 Phase 3 Ibandronate;Zoledronate
37 Phase II Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma Unknown status NCT02409524 Phase 2
38 Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck. Unknown status NCT01998542 Phase 1, Phase 2
39 An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Unknown status NCT02624999 Phase 2 Cisplatin
40 A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens Unknown status NCT01502085 Phase 1, Phase 2 Vorinostat, Lenalinomide and Dexamethasone
41 N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery. Completed NCT00122018 Phase 2 N-acetylcysteine;fenoldopam
42 An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure Completed NCT01270932 Phase 2 Lenalidomide and Dexamethasone
43 Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells Completed NCT00923845 Phase 2 Pentostatin;Sirolimus;Cyclophosphamide
44 The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies. Completed NCT00593580 Phase 2 placebo;alendronate/cholecalciferol
45 Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial Completed NCT02347501 Phase 2 Sitagliptin (Januvia)
46 Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. Completed NCT01991197 Phase 2 Sitagliptin;Gliclazide;Sitagliptin matched placebo;Gliclazide matched placebo capsule
47 Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Recruiting NCT03448718 Phase 2 Olaparib
48 Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03599960 Phase 2 Chemotherapy
49 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation Recruiting NCT03159702 Phase 2 Evomela;Fludarabine
50 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab

Search NIH Clinical Center for Creatinine Clearance Quantitative Trait Locus

Sources

Genetic Tests for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Anatomical Context for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards organs/tissues related to Creatinine Clearance Quantitative Trait Locus:

41
Kidney, Heart, Bone, Liver, Lung, Skin, Testes
Sources

Publications for Creatinine Clearance Quantitative Trait Locus

About this section

Articles related to Creatinine Clearance Quantitative Trait Locus:

(show top 50) (show all 1437)
# Title Authors PMID Year
1
A genome scan for renal function among hypertensives: the HyperGEN study. 8
11115379 2001
2
Toxicity and effectiveness of carboplatin in obese or overweight patients. 38
30086680 2019
3
Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. 38
31392910 2019
4
Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. 38
31129889 2019
5
Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. 38
31423601 2019
6
Preparation of Ganoderma lucidum polysaccharide‑chromium (III) complex and its hypoglycemic and hypolipidemic activities in high-fat and high-fructose diet-induced pre-diabetic mice. 38
31401268 2019
7
The effect of tibial plateau leveling osteotomy on patellofemoral kinematics in dogs: An in vivo study. 38
31373719 2019
8
Recommendations for rehabilitation after surgical treatment of cranial cruciate ligament disease in dogs: A 2017 survey of veterinary practitioners. 38
31390083 2019
9
Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma. 38
31388085 2019
10
Comparative histomorphometric analysis of cellular phenotype in canine stifle ligaments and tendon. 38
31056780 2019
11
Osmotic diuresis in chronic kidney disease: its significance and clinical utility. 38
31214953 2019
12
Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial. 38
31078666 2019
13
Worsening renal function, adverse clinical events and major determinants for changes of renal function in patients with atrial fibrillation: a Japanese multicenter registry substudy. 38
31204852 2019
14
Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation. 38
30581104 2019
15
Investigating subtle kidney injury in primary hyperparathyroidism by means of sensitive and specific biomarkers. 38
31309599 2019
16
Real-life behaviour of direct oral anticoagulants in a Spanish cohort with nonvalvular atrial fibrillation: Refase Registry. 38
31335222 2019
17
Simulation of Heavy Metals Migration in Soil-Wheat System of Mining Area. 38
31319513 2019
18
Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. 38
31317556 2019
19
Safety of dose-reduced pemetrexed in patients with renal insufficiency. 38
29871545 2019
20
Midostaurin administration in two hemodialysis patients. 38
30253726 2019
21
Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana. 38
31331365 2019
22
Amlodipine and calcineurin inhibitor-induced nephrotoxicity following allogeneic hematopoietic stem cell transplant. 38
31177566 2019
23
Relationship between hemoglobin levels and vancomycin clearance in patients with sepsis. 38
30868193 2019
24
Blood Urea Nitrogen Levels to Verify Estimated Glomerular Filtration Rate, as Derived from 2 Commonly Used Equations. 38
30892611 2019
25
Factors related to inappropriate edoxaban use. 38
31292978 2019
26
Appropriateness of dabigatran dosing in patients with nonvalvular atrial fibrillation (NVAF): A retrospective study conducted in a tertiary care university hospital in the eastern province of Saudi Arabia. 38
31198397 2019
27
Evolution of interlayer and intralayer magnetism in three atomically thin chromium trihalides. 38
31110023 2019
28
Oral mucosa and salivary findings in non-diabetic patients with chronic kidney disease. 38
31078070 2019
29
Preparation of a novel Grifola frondosa polysaccharide-chromium (III) complex and its hypoglycemic and hypolipidemic activities in high fat diet and streptozotocin-induced diabetic mice. 38
30851330 2019
30
Atomically Thin CrCl3: An In-Plane Layered Antiferromagnetic Insulator. 38
31083954 2019
31
Circulating leptin levels predict the decline in renal function with age in a sample of adult men (The Olivetti Heart Study). 38
30117101 2019
32
Is serum uric acid a predictor of long-term renal outcome in lupus nephritis? 38
31154554 2019
33
Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. 38
31084339 2019
34
Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment. 38
31056857 2019
35
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. 38
31127325 2019
36
Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. 38
31073827 2019
37
Corrosion Behavior of GH4169 Alloy under Alternating Oxidation at 900 °C and Solution Immersion. 38
31072033 2019
38
Ruthenium trichloride catalyzed conversion of cellulose into 5-hydroxymethylfurfural in biphasic system. 38
30711756 2019
39
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. 38
31053098 2019
40
Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. 38
30913984 2019
41
Performance of creatinine clearance and estimated GFR in assessing kidney function in living donor candidates. 38
31205262 2019
42
Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis. 38
31068485 2019
43
Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. 38
31111434 2019
44
A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. 38
31248681 2019
45
Functional Anatomy of the Craniomedial and Caudolateral Bundles of the Cranial Cruciate Ligament in Beagle Dogs. 38
30873569 2019
46
Evaluation of recovery of limb function by use of force plate gait analysis after tibial plateau leveling osteotomy for management of dogs with unilateral cranial cruciate ligament rupture. 38
31034268 2019
47
A Novel CNN-Based CAD System for Early Assessment of Transplanted Kidney Dysfunction. 38
30976081 2019
48
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. 38
30423165 2019
49
Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention. 38
30987432 2019
50
Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. 38
30496913 2019
Sources

Variations for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Expression for Creatinine Clearance Quantitative Trait Locus

About this section
Search GEO for disease gene expression data for Creatinine Clearance Quantitative Trait Locus.
Sources

Pathways for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

GO Terms for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Sources for Creatinine Clearance Quantitative Trait Locus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....